Novasep Revenue and Competitors

Marcus Hook, PA USA

Location

N/A

Total Funding

Chemicals

Industry

Estimated Revenue & Valuation

  • Novasep's estimated annual revenue is currently $300M per year.(i)
  • Novasep's estimated revenue per employee is $455,235

Employee Data

  • Novasep has 659 Employees.(i)
  • Novasep grew their employee count by -17% last year.

Novasep's People

NameTitleEmail/Phone
1
CEO & ChairmanReveal Email/Phone
2
Head Manufacturing Science and TechnologyReveal Email/Phone
3
VP Business DevelopmentReveal Email/Phone
4
Chief Legal OfficerReveal Email/Phone
5
Human Resources & Communication DirectorReveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
DirectorReveal Email/Phone
8
Project Management OfficerReveal Email/Phone
9
HR & Site Administration ManagerReveal Email/Phone
10
Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.5M180%N/AN/A
#2
$1700M36153%N/AN/A
#3
$7.5M710%N/AN/A
#4
$1180M25715%N/AN/A
#5
$3.5M467%N/AN/A
#6
$7.5M51-19%N/AN/A
#7
$7.5M12-20%N/AN/A
#8
N/A274%N/AN/A
#9
$7.5M330%N/AN/A
#10
N/A90%N/AN/A
Add Company

What Is Novasep?

Novasep serves Life Sciences industries, such as human health, animal health, cosmetics, food additives, agrochemicals. Novasep designs purification processes aimed at producing a variety of biomolecules like: Vaccines and vitamins Proteins and enzymes Peptides and antibiotics Milk proteins and amino acid derivatives Sweeteners of various types The synthesis of organic molecules, either advanced intermediates or APIs (Active Pharlaceutical Ingredients) is often carried out by integrating the purification technologies mastered by the group. This combination that impoves synthetic pathways of molecules is used every day to develop and produce our customers' innovative drugs. Current applications are found with drugs that treat: Cancer Cardiovascular disorders, i.e. high blood pressure

keywords:N/A

N/A

Total Funding

659

Number of Employees

$300M

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Novasep News

2022-04-20 - First-quarter results 2022 of Sartorius Stedim Biotech

In addition, the acquisition of the chromatography business of Novasep further strengthened our positioning in downstream processing.

2022-04-17 - Viral Vector Manufacturing Market Size And Forecast | Novasep ...

Novasep, Brammer Bio, Lonza, Cobra Biologics, Oxford Biomedica, Finvector Vision Therapies, Merck KGaA, Spark Therapeutics, uniQure, Merck.

2022-04-06 - PharmaZell, Novasep merger creates new CDMO, API manufacturer

Michel Spagnol, the former CEO of Novasep, will join the new company's board of directors. He said, “I have great confidence that the group...